Do Changes in ctDNA Predict Response for Patients With Oesophageal Cancer Receiving Durvalumab

PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 30, 2018

Primary Completion Date

November 11, 2021

Study Completion Date

June 30, 2026

Conditions

Oesophageal Cancer

Interventions

DRUG

Durvalumab

Durvalumab will be administered via an infusion in the arm, over a duration of up to 1 hour.

Trial Locations (1)

Cambridge University Hospitals NHS Foundation Trust, Cambridge